TEVATEVA PHARMACEUTICAL INDUSTR...

NYSE tevapharm.com


$ 17.97 $ 0.44 (2.51 %)    

Wednesday, 11-Sep-2024 15:59:54 EDT
QQQ $ 468.28 $ 9.96 (2.17 %)
DIA $ 409.73 $ 1.01 (0.25 %)
SPY $ 554.79 $ 5.63 (1.03 %)
TLT $ 100.61 $ -0.08 (-0.08 %)
GLD $ 232.25 $ -0.37 (-0.16 %)
$ 17.96
$ 17.96 x 1,000
$ 17.97 x 1,200
-- - --
$ 8.06 - $ 19.08
8,703,238
na
20.35B
$ 1.15
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 02-12-2024 12-31-2023 10-K
4 11-09-2023 09-30-2023 10-Q
5 08-02-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 02-10-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 07-27-2022 06-30-2022 10-Q
10 05-03-2022 03-31-2022 10-Q
11 02-09-2022 12-31-2021 10-K
12 10-27-2021 09-30-2021 10-Q
13 07-28-2021 06-30-2021 10-Q
14 04-28-2021 03-31-2021 10-Q
15 02-10-2021 12-31-2020 10-K
16 11-05-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 02-21-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-02-2019 03-31-2019 10-Q
23 02-19-2019 12-31-2018 10-K
24 11-01-2018 09-30-2018 10-Q
25 08-02-2018 06-30-2018 10-Q
26 05-03-2018 03-31-2018 10-Q
27 02-12-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 unitedhealth-follows-competitors-replaces-humira-with-lower-cost-biosimilars

UnitedHealth will remove AbbVie's Humira from its preferred drug lists by 2025, opting for lower-cost biosimilars like Amge...

 teva-announces-80m-settlement-to-baltimore-city-continues-opioid-litigation-against-other-companies

Baltimore secures an $80 million settlement with Teva Pharmaceuticals in its opioid crisis litigation. Funds will be allocated ...

Core News & Articles

- Reuters Citing Sources

 jp-morgan-shows-most-interest-in-teva-organon-as-specialty-pharma-sector-exhibits-signs-of-stability

JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva,...

 shortage-relief-more-takedas-vyvanse-for-adhd-on-the-way-as-us-ramps-up-production

Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and gl...

 ubs-maintains-buy-on-teva-pharmaceutical-indus-raises-price-target-to-26

UBS analyst Ashwani Verma maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $24 to...

 novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets

Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite co...

 barclays-maintains-overweight-on-teva-pharmaceutical-indus-raises-price-target-to-22

Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...

 tech-stocks-on-track-for-best-session-in-5-months-ahead-of-fed-meeting-small-caps-target-highest-close-since-january-2022-whats-driving-markets-wednesday

Tech stocks soared to their best session in five months on Wednesday, ahead of the highly anticipated Federal Open Market Commi...

 teva-beats-q2-estimates-raises-annual-outlook-on-strong-generic-austedo-sales

Teva Pharmaceutical reported Q2 2024 sales of $4.16 billion, surpassing the $4.06 billion consensus. Revenue rose 7% YoY, drive...

 wall-street-remains-on-track-for-amd-led-rebound-ahead-of-fed-decision-meta-earnings-analyst-says-the-bull-tends-to-remain-despite-near-term-volatility

Tech optimism is likely to abound on Wall Street as AI-levered stocks are feeding off the strength generated by Advanced Micro ...

 teva-pharmaceutical-expects-2024-revenues-of-160b-164b-versus-prior-guidance-of-157b-163b-and-consensus-of-16012b

Outlook for 2024 Non-GAAP Results $ billions, except EPS or as noted July 2024 Outlook January 2024 Outlook ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION